FDA Approves Blincyto to Treat Rare Form of Leukemia
The U.S. Food and Drug Administration today approved Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL.
Immune Diseases Were More Common in Those Born by C-Section
Could the birth process have a role in immune disease development? A common birthing method may raise babies' risk of immune diseases later, a new study found.
FDA Expands Approval of Rx for Rare Blood and Bone Disease
Earlier this year, the US Food and Drug Administration (FDA) gave a speedy approval to a new medication to treat a rare blood disease. Now, the FDA has expanded that approval.
FDA Approves New Cancer Medication
The US Food and Drug Administration (FDA) approved Zydelig (idelalisib) today to treat patients with three types of blood cancers.
Many Minority Kids With Cancer Missed Needed Medication
Children in remission from leukemia, the most common childhood cancer, need to take a certain medication to keep the cancer from coming back. But some of these children are not receiving all the medication they need.
FDA Approves New Leukemia Treatment
The FDA has given some leukemia patients a new treatment option.
Why Childhood Cancer Survival Rates Have Increased
With increasing survival rates for many types of childhood cancers, some of these cancers are approaching cures. Several key events have made this possible.
Traffic May be Deadly, But Not the Way You’d Expect
Many people consider living near traffic to be dangerous for children, fearing accidents. New research suggests that traffic can be harmful to children for other reasons.
Turning Leukemia into a Highly Treatable Disease
Chemotherapy is a standard treatment for the most common form of leukemia — chronic lymphocytic leukemia (CLL). A combination of pills may offer CLL patients new, better and gentler options.
Using Genetic Engineering to Treat Cancer
Many leukemias can be treated successfully, but if the disease doesn’t respond, patients are left with few options. A new therapy may change all that.